Memorial Sloan Kettering Cancer Center
KarMMa-3 results: ide-cel vs standard regimens in triple-class exposed multiple myeloma
Sergio Giralt • 17 Feb 2023
Challenges with CAR-T therapy in AML & insights into IF-BETTER-gated CAR-T cells
Sascha Haubner • 10 Feb 2023
Adoptive T cell therapies for solid tumors: what are the key challenges?
Chris Klebanoff • 1 Apr 2022